RxDoctor Payments Data

Ulysses Walls, MD

Cardiovascular Disease · Alpena, MINPI 1932101789

Payments from drug & device makers

$20,346in general payments, 2019–2025

Across 557 payments — averaging $36.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • AstraZeneca$2K
  • Novartis$2K
  • Boehringer Ingelheim$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Merck$908
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$4352%
  • Speaking & faculty fees$9,40046%
  • Travel & lodging$6853%
  • Food & beverage$9,75148%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,346 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$406,657
Medicare patients
494
Services billed
5,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban512$541,326
JardianceEmpagliflozin177$167,808
EntrestoSacubitril/Valsartan107$114,073
XareltoRivaroxaban71$75,741
FarxigaDapagliflozin Propanediol40$43,121
OzempicSemaglutide33$35,459
Repatha SureclickEvolocumab35$28,259
BrilintaTicagrelor21$19,239
Metoprolol Succinate757$12,143
Rosuvastatin Calcium673$9,740
KerendiaFinerenone11$8,039
Losartan Potassium554$7,057
Diltiazem 24hr Er (Cd)Diltiazem Hcl171$4,767
ClopidogrelClopidogrel Bisulfate238$3,390
Bumetanide48$2,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$9,773$541,326512 claims
Boehringer IngelheimJardiance$1,526$167,808177 claims
NovartisEntresto$1,727$114,073107 claims
Johnson & JohnsonXarelto$516$75,74171 claims
AstraZenecaFarxiga, Brilinta$2,428$62,36061 claims
Novo NordiskOzempic$268$35,45933 claims
BayerKerendia$475$8,03911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Alpena

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →